LUNG Pulmonx Corp

Price (delayed)

$7.77

Market cap

$301.6M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.54

Enterprise value

$271.78M

Pulmonx Corporation is a commercial-stage medical technology company. The Company is focused on providing planning tools and treatments for obstructive lung disease. Its solutions include Zephyr Valve, Chartis Pulmonary Assessment ...

Highlights
Pulmonx's gross profit has increased by 28% YoY and by 7% from the previous quarter
The revenue has grown by 27% YoY and by 6% from the previous quarter
The quick ratio is down by 37% year-on-year but it is up by 7% since the previous quarter
The company's equity fell by 23% YoY and by 7% QoQ

Key stats

What are the main financial stats of LUNG
Market
Shares outstanding
38.82M
Market cap
$301.6M
Enterprise value
$271.78M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.71
Price to sales (P/S)
4.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.72
Earnings
Revenue
$72.99M
EBIT
-$54.55M
EBITDA
-$50.29M
Free cash flow
-$37.96M
Per share
EPS
-$1.54
Free cash flow per share
-$0.98
Book value per share
$2.87
Revenue per share
$1.89
TBVPS
$4.2
Balance sheet
Total assets
$164.58M
Total liabilities
$54.09M
Debt
$40.57M
Equity
$110.5M
Working capital
$126.64M
Liquidity
Debt to equity
0.37
Current ratio
6.95
Quick ratio
5.96
Net debt/EBITDA
0.59
Margins
EBITDA margin
-68.9%
Gross margin
74.3%
Net margin
-80.5%
Operating margin
-82.3%
Efficiency
Return on assets
-32.6%
Return on equity
-48.1%
Return on invested capital
-49.3%
Return on capital employed
-38.1%
Return on sales
-74.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LUNG stock price

How has the Pulmonx stock price performed over time
Intraday
4.72%
1 week
20.47%
1 month
34.66%
1 year
-42.36%
YTD
-39.06%
QTD
22.56%

Financial performance

How have Pulmonx's revenue and profit performed over time
Revenue
$72.99M
Gross profit
$54.24M
Operating income
-$60.07M
Net income
-$58.73M
Gross margin
74.3%
Net margin
-80.5%
Pulmonx's gross profit has increased by 28% YoY and by 7% from the previous quarter
The revenue has grown by 27% YoY and by 6% from the previous quarter
Pulmonx's net margin has increased by 22% YoY and by 9% QoQ
Pulmonx's operating margin has increased by 20% YoY and by 9% from the previous quarter

Growth

What is Pulmonx's growth rate over time

Valuation

What is Pulmonx stock price valuation
P/E
N/A
P/B
2.71
P/S
4.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.72
Pulmonx's EPS has increased by 3.8% from the previous quarter and by 2.5% YoY
The P/B is 26% lower than the last 4 quarters average of 3.5
The company's equity fell by 23% YoY and by 7% QoQ
The price to sales (P/S) is 40% less than the last 4 quarters average of 6.6
The revenue has grown by 27% YoY and by 6% from the previous quarter

Efficiency

How efficient is Pulmonx business performance
The company's return on equity fell by 29% YoY and by 3.2% QoQ
Pulmonx's ROS has increased by 25% YoY and by 10% from the previous quarter
LUNG's return on invested capital is up by 15% year-on-year and by 3.7% since the previous quarter
The ROA fell by 12% YoY

Dividends

What is LUNG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LUNG.

Financial health

How did Pulmonx financials performed over time
The quick ratio is down by 37% year-on-year but it is up by 7% since the previous quarter
Pulmonx's current ratio has decreased by 35% YoY but it has increased by 7% from the previous quarter
Pulmonx's debt is 63% lower than its equity
The debt to equity has increased by 23% year-on-year and by 6% since the previous quarter
The company's equity fell by 23% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.